2,989
Participants
Start Date
January 11, 2019
Primary Completion Date
November 23, 2022
Study Completion Date
November 23, 2022
Bivalirudin
IV infusion of 0.2 mg/kg/h (low-rate infusion) for at least 48h after the procedure or until discharge from CCU if it occurs later
Enoxaparin
40mg/d s.c.for at least 48h after the procedure or until discharge from CCU if it occurs later
Unfractionated heparin
IV infusion of 10 U/kg/h (maximum 1000 U) initially, adjusted to maintain ACT between 150 and 220 seconds for at least 48h after the procedure or until discharge from CCU if it occurs later
Bivalirudin placebo
Matching placebo IV infusion for at least 48h after the procedure or until discharge from CCU if it occurs later
Enoxaparin placebo syringe
Placebo syringe will be only prepared by a designated unblended medical professional on site. Placebo syringe will be presented in identical containers as a clear, colorless, sterile liquid of saline.Subcutaneous injection once a day for at least 48 hours after the procedure or until discharge from CCU if it occurs later.
Unfractionated heparin placebo
Matching placebo IV infusion for at least 48h after the procedure or until discharge from CCU if it occurs later.
Beijing Anzhen Hospital, Capital Medical University, Beijing
Chinese Academy of Medical Sciences, Fuwai Hospital
OTHER
ACTION Study Group (Pitié-Salpêtrière Hospital), Paris, France
UNKNOWN
Beijing Anzhen Hospital
OTHER